Panel advances bill creating guardrails for stem‑cell and regenerative therapies
Get AI-powered insights, summaries, and transcripts
Sign Up Free
Summary
The committee approved SB 12‑14 to regulate certain stem‑cell and regenerative therapies not fully FDA‑approved, requiring provider training, sourcing standards, informed consent and reporting; proponents framed it as consumer protection against bad actors.
Senate Bill 12‑14 would establish a state regulatory framework for certain stem‑cell and regenerative therapies derived from birth tissues and other post‑birth biologics when those therapies are not broadly FDA‑approved.
Sponsor Sen. Schamp described the bill as a set of “guardrails” that would let qualified licensed providers offer selected therapies under disclosure, accreditation and reporting requirements while creating civil remedies for patients who receive treatments that violate statutory requirements.
Supporters included providers and industry representatives who argued that a regulated pathway prevents shady operators from exploiting patients and allows promising treatments to be delivered transparently in‑state. Brigham Bueller, who runs an Austin clinic that uses cellular biologics, said regulated pathways reduce the incentives for patients to travel abroad for unregulated care.
Physicians and groups supporting the bill urged strict sourcing and record‑keeping standards; Stem Cell Doctors of Arizona and other clinician advocates said transparency and accredited storage facilities are essential. The committee adopted an amendment and gave the bill a due‑pass recommendation.
Why it matters: The bill attempts to balance provider innovation and patient safety in a fast‑moving field. It would create new licensing and reporting obligations for Arizona providers who administer specified therapies.
Attribution: Testimony and descriptions are sourced to Senator Schamp, Brigham Bueller and Gibson McKay as recorded in committee proceedings.